Please enable Javascript
Hematology & Blood Cancer
Advertisement
Novel Trio of Bortezomib, Dexamethasone, and Daratumumab in Pediatric Plasmacytic PTLD Treatment
Dustin Samples
Lymphoma
|
February 15, 2023
A case series demonstrated the effectiveness of a novel trio for pediatric plasmacytic PTLD.
Read More
Technology-Based Psychosocial Intervention for Adolescent and Young Adult Survivors of ALL
Dustin Samples
Leukemia
|
January 17, 2023
Adolescents and young adults face different challenges than older survivors of ALL. Can technology improve these challenges?
Read More
CAR T-Cell Referral Linked With High Psychological Distress
Leah Lawrence
Treatment
|
January 10, 2023
Prognostic understanding is essential to medical decision-making, but are these patients' hopes too high?
Read More
3 Strategies for Preparing for a QOPI® Survey
Kate B. Hubbard, MSN, RN, OCN®, NPD-BC
Best Practices
|
January 9, 2023
Accreditation and certification surveys validate an organization's quality of care. How can your organization be prepared?
Read More
Nurses Vital Part of Team-Based Care for HSCT Patients with Hepatic VOD/SOD
Dustin Samples
Hematology & Blood Cancer
|
January 6, 2023
Interprofessional team-based care is the standard for patients undergoing HSCT. But who belongs on the team?
Read More
Increased Communication Decreased Time to Chemotherapy Administration
Leah Lawrence
Hematology & Blood Cancer
|
October 12, 2022
Care teams at Thomas Jefferson University Hospital decreased time to chemotherapy administration by using new strategies.
Read More
Blood Test Could Predict Neurotoxicity Associated With CAR T-Cell Therapy
Leah Lawrence
Hematology & Blood Cancer
|
September 20, 2022
ICANS, a complication of CAR T cell therapy, was associated with an injury that is detectable with a blood test.
Read More
Tablet Treatment for Blood Cancers Approved by FDA
Emily Menendez
Hematology & Blood Cancer
|
September 1, 2022
The tablet form of blood cancer drug acalabrutinib has been FDA approved, making administration easier for certain patients.
Read More
Quality of Life Comparison: Blood Cancer Patients on Clinical Trials Versus Patients in Standard Care
Teresa Hagan Thomas, PhD, RN
Treatment
|
July 12, 2022
One concern that keeps patients from enrolling in clinical trials is the belief that their quality of life will suffer.
Read More
What’s New: Oral Chronic GVHD Incidence Even Decades After SCT
Elaine S. DeMeyer, RN, MSN, AOCN®, BMTCN®
GVHD
|
June 27, 2022
Patients who receive a transplant at a young age may experience GVHD symptoms decades later, like oral chronic GVHD.
Read More
Determining the Optimal Anti-Thymocyte Globulin Exposure in Haploidentical Peripheral Blood Stem Cell Transplantation
Patrick Daly
Hematology & Blood Cancer
|
March 24, 2022
Anti-thymocyte globulin (ATG) is used in conditioning prior to allogeneic hematopoietic stem cell transplantation for acute ...
Read More
Black Patients are Under-Represented in Pivotal CAR T-Cell Clinical Trials
Ariel Jones
Conferences
|
December 18, 2021
Pivotal trials that supported FDA approval of CAR T-cell therapies had low proportions of Black patients enrolled.
Read More
Younger MCL Patients Have Sustained Benefit of Cytarabine Pre-Transplant Conditioning
Ariel Jones
Conferences
|
December 17, 2021
These findings were presented at the 2021 American Society of Hematology Annual Meeting.
Read More
Polatuzumab Vetodin Plus R-CHP Reduces Risk of Disease Progression or Death in Newly Diagnosed DLBCL
Ariel Jones
Conferences
|
December 17, 2021
Hervé Tilly, MD, of Centre Henri Becquerel and University of Rouen in France, presented the new research at ASH 2021.
Read More
High-Dose Methotrexate Fails to Lower CNS Relapse Risk in Aggressive B-cell Lymphoma
Ariel Jones
Conferences
|
December 16, 2021
This lack of benefit was seen in the entire study population.
Read More
Cytopenias Could Represent an Early Marker of Cancer Mortality Risk
Ariel Jones
Conferences
|
December 16, 2021
eripheral blood cytopenias may be associated with a higher risk of cancer-related mortality, particularly in Black patients.
Read More
SEQUOIA: Zanubrutinib and Venetoclax Combination Is Well-Tolerated, Effective as First-Line Therapy
Ariel Jones
Conferences
|
December 16, 2021
This is according to preliminary data from a nonrandomized arm of the SEQUOIA trial.
Read More
Liso-cel Outperforms Standard of Care as Second-Line Therapy in Relapsed/Refractory LBCL
Ariel Jones
Conferences
|
December 16, 2021
The CAR T-cell therapy significantly improved event-free survival (EFS) compared with standard of care in patients with LBCL.
Read More
Could Circulating Tumor DNA Offer a New Noninvasive Tool for CNSL Prediction?
Ariel Jones
Conferences
|
December 14, 2021
According to new research, circulating tumor DNA (ctDNA) accurately reflects tumor burden.
Read More
Mosunetuzumab Plus Polatuzumab Vedotin Shows Promise in Relapsed/Refractory B-Cell NHL
Ariel Jones
Conferences
|
December 14, 2021
Investigator L. Elizabeth Budde, MD, PhD, presented the research at the 2021 ASH Annual Meeting.
Read More
Load More
Advertisement
Advertisement
Advertisement